The impact of lenalidomide exposure on response and outcomes in patients with lower-risk myelodysplastic syndromes and del(5q)-Reference-Cited by-同舟云学术

The impact of lenalidomide exposure on response and outcomes in patients with lower-risk myelodysplastic syndromes and del(5q)

Published:2018-09-21 Issue:10 Volume:8 Page:
ISSN:2044-5385
Container-title:Blood Cancer Journal
language:en
Short-container-title:Blood Cancer Journal

Author:

Sekeres Mikkael A.,Swern Arlene S.,Giagounidis Aristoteles,List Alan F.,Selleslag Dominik,Mittelman Moshe,Schlegelberger Brigitte,Göhring Gudrun,Li Jack Shiansong,Sugrue Mary M.,Fenaux Pierre

Publisher

Springer Science and Business Media LLC

Subject

Oncology,Hematology

Link

http://www.nature.com/articles/s41408-018-0126-z.pdf

Reference10 articles.

1. Greenberg, P. et al. International scoring system for evaluating prognosis in myelodysplastic syndromes. Blood 89, 2079–2088 (1997).

2. Sekeres, M. A. et al. Characteristics of US patients with myelodysplastic syndromes: results of six cross-sectional physician surveys. J. Natl Cancer Inst. 100, 1542–1551 (2008).

3. Greenberg, P. L. et al. Revised international prognostic scoring system (IPSS-R) for myelodysplastic syndromes. Blood 120, 2454–2465 (2012).

4. Fenaux, P. & Adès, L. How we treat lower-risk myelodysplastic syndromes. Blood 121, 4280–4286 (2013).

5. Gerds, A. T. & Sekeres, M. A. Initial transfusion frequency and survival in myelodysplastic syndromes: hopping onto a fast train to nowhere. Leuk. Lymphoma 55, 2221–2222 (2014).

Cited by 9 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. A myelodysplastic neoplasm with del(5q) treated with luspatercept uncovers unexplored mechanisms of action for the drug;British Journal of Haematology;2024-08-18

2. New-Onset Monosomy 7-Induced Pancytopenia in a 66-Year-Old Woman;Cureus;2024-01-29

3. Cancer drugs with high repositioning potential for Alzheimer’s disease;Expert Opinion on Emerging Drugs;2023-10-02

4. Moving toward a conceptualization of measurable residual disease in myelodysplastic syndromes;Blood Advances;2023-08-10

5. Novel Strategies to Manage Cytopenia in Low-Risk MDS;Pathogenesis and Treatment of Leukemia;2023